Successful Treatment of Severe Steroid-Resistant Engraftment Syndrome Following Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with Emapalumab: A Case Report

References

• Adhikari J, Sharma P, Bhatt VR. Optimal graft source for allogeneic hematopoietic stem cell transplant: bone marrow or peripheral blood? Future Oncol. 2016;12(15):1823–1832. doi:10.2217/fon-2016-0106
   PubMed Web of Science ®Google Scholar
• Jagasia M, Arora M, Flowers ME, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296–307. doi:10.1182/blood-2011-06-364265
   PubMed Web of Science ®Google Scholar
• Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin. 2019;37(4):569–582. doi:10.1016/j.det.2019.05.014
   PubMed Web of Science ®Google Scholar
• Carreras E, Fernández-Avilés F, Silva L, et al. Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant. 2010;45(9):1417–1422. doi:10.1038/bmt.2009.363
   PubMed Web of Science ®Google Scholar
• Chang YJ, Pei XY, Huang XJ. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet Haematol. 2022;9(12):e919–e929. doi:10.1016/S2352-3026(22)00293-9
   PubMed Web of Science ®Google Scholar
• Sheth V, Jain R, Gore A, Ghanekar A, Saikia T. Engraftment syndrome: clinical features and predictive factors in autologous stem cell transplant. Indian J Hematol Blood Transfus. 2018;34(3):448–453. doi:10.1007/s12288-017-0899-4
   PubMed Web of Science ®Google Scholar
• Jin L, Sun Z, Liu H, et al. Inflammatory monocytes promote pre-engraftment syndrome and tocilizumab can therapeutically limit pathology in patients. Nat Commun. 2021;12(1):4137. doi:10.1038/s41467-021-24412-1
   PubMed Web of Science ®Google Scholar
• Maqbool S, Nadeem M, Shahroz A, et al. Engraftment syndrome following Hematopoietic stem cell transplantation: a systematic approach toward diagnosis and management. Med Oncol. 2022;40(1):36. doi:10.1007/s12032-022-01894-7
   PubMed Web of Science ®Google Scholar
• Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children With Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020;382(19):1811–1822. doi:10.1056/NEJMoa1911326
   PubMed Web of Science ®Google Scholar
• Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27(9):893–898. doi:10.1038/sj.bmt.1703015
   PubMed Web of Science ®Google Scholar
• Cornell RF, Hari P, Drobyski WR. Engraftment syndrome after autologous stem cell transplantation: an update unifying the definition and management approach. Biol Blood Marrow Transplant. 2015;21(12):2061–2068. doi:10.1016/j.bbmt.2015.08.030
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Lim Y-J, Kim J-Y, Kim Y-D, Lee S-W. Pre-engraftment syndrome in hematopoietic stem cell transplantation. J Korean Med Sci. 2008;23(1):98–103. doi:10.3346/jkms.2008.23.1.98
   PubMed Web of Science ®Google Scholar
• Iguchi A, Terashita Y, Sugiyama M, et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation. Pediatr Transplant. 2016;20(1):114–119. doi:10.1111/petr.12621
   PubMed Web of Science ®Google Scholar
• Khandelwal P, Mellor-Heineke S, Rehman N, et al. Cytokine profile of engraftment syndrome in pediatric hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2016;22(4):690–697. doi:10.1016/j.bbmt.2015.12.016
   PubMed Web of Science ®Google Scholar
• Grant A, Chapman LRM, Mitchell R, O’Brien TA. Engraftment syndrome following hematopoietic stem cell transplant: a review of the literature. Clin Transplant. 2020;34(6):e13875. doi:10.1111/ctr.13875
   PubMed Web of Science ®Google Scholar
• Isobe M, Konuma T, Kato S, et al. Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myelogenous leukemia after single cord blood transplantation. Biol Blood Marrow Transplant. 2019;25(6):1187–1196. doi:10.1016/j.bbmt.2019.02.007
   PubMed Web of Science ®Google Scholar
• Konuma T, Kohara C, Watanabe E, et al. Cytokine profiles of pre-engraftment syndrome after single-unit cord blood transplantation for adult patients. Biol Blood Marrow Transplant. 2017;23(11):1932–1938. doi:10.1016/j.bbmt.2017.07.020
   PubMed Web of Science ®Google Scholar
• Abongwa C, Abu-Arja R, Rumelhart S, Lazarus HM, Abusin G. Favorable outcome to glucocorticoid therapy for engraftment syndrome in pediatric autologous hematopoietic cell transplant. Pediatr Transplant. 2016;20(2):297–302. doi:10.1111/petr.12652
   PubMed Web of Science ®Google Scholar
• Koreth J, Biernacki M, Aldridge J, et al. Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011;17(3):421–428. doi:10.1016/j.bbmt.2010.09.013
   PubMed Web of Science ®Google Scholar
• Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033–1045. doi:10.1007/s00262-008-0620-4
   PubMed Web of Science ®Google Scholar
• Badar T, Khan MA, Szabo A, et al. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019;26(4):210–215. doi:10.1080/13506129.2019.1645001
   PubMed Web of Science ®Google Scholar
• Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol. 2021;12:614704. doi:10.3389/fimmu.2021.614704
   PubMed Web of Science ®Google Scholar
• Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4):101515. doi:10.1016/j.berh.2020.101515
   PubMed Web of Science ®Google Scholar
• Merli P, Quintarelli C, Strocchio L, Locatelli F. The role of interferon-gamma and its signaling pathway in pediatric hematological disorders. Pediatr Blood Cancer. 2021;68(4):e28900. doi:10.1002/pbc.28900
   PubMed Web of Science ®Google Scholar
• Jenkins MR, Rudd-Schmidt JA, Lopez JA, et al. Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015;212(3):307–317. doi:10.1084/jem.20140964
   PubMed Web of Science ®Google Scholar
• Carter SJ, Tattersall RS, Ramanan AV. Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment. Rheumatology. 2019;58(1):5–17. doi:10.1093/rheumatology/key006
   PubMed Web of Science ®Google Scholar
• Bauchmuller K, Manson JJ, Tattersall R, et al. Haemophagocytic lymphohistiocytosis in adult critical care. J Intensive Care Soc. 2020;21(3):256–268. doi:10.1177/1751143719893865
   PubMedGoogle Scholar
• Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273. doi:10.1056/NEJMra2026131
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18(9):545–558. doi:10.1038/s41577-018-0029-z
   PubMed Web of Science ®Google Scholar
• Merli P, Caruana I, De Vito R, et al. Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019;104(11):2314–2323. doi:10.3324/haematol.2019.216101
   PubMed Web of Science ®Google Scholar
• Choi J, Ziga ED, Ritchey J, et al. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120(19):4093–4103. doi:10.1182/blood-2012-01-403196
   PubMed Web of Science ®Google Scholar